Related Experiment Video
Updated: May 23, 2026

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential
Published on: May 25, 2020
A validated risk calculator to assess risk and rate of visual field progression in treated glaucoma patients
Carlos Gustavo De Moraes1, Mitra Sehi, David S Greenfield
1Einhorn Clinical Research Center, New York Eye and Ear Infirmary, New York, New York 10003, USA. demoraesmd@gmail.com
Purpose:
The purpose of our study is to develop and validate a model to predict visual field (VF) outcomes in patients with treated glaucoma.
Methods:
Data from 587 eyes with treated glaucoma evaluated in a cohort were used to develop two equations to predict VF outcomes, one estimating the risk of progression (%) and another estimating the global rate of VF sensitivity change (decibels [dB]/year). These equations, which included variables associated with VF progression in a multivariable model, then were tested in another cohort (n = 62 eyes) followed for at least 4 years. Agreement, discrimination, and calibration of the model in the validation sample were assessed as main outcome measures.
Results:
The mean difference between observed and predicted global rates of sensitivity change was 0.13 dB/year (95% confidence interval [CI] = 0.06 to 0.18 dB/year) and the mean difference between observed and predicted final VF mean deviation (MD) values was 0.37 dB (95% CI = 0.00 to 0.75 dB). The predictive model had moderate discriminative ability to estimate VF progression in the independent sample (c-index of 0.78, 95% CI = 0.59 to 0.97).
Conclusions:
To our knowledge, this is the first attempt to generate and validate a risk model for patients with treated glaucoma. The prediction model showed moderate accuracy in estimating future VF outcomes in an independent glaucoma population, and may be useful for the objective assessment of risk of progressive VF loss.
Related Concept Videos
Glaucoma: Overview
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
